Paralysis News and Research RSS Feed - Paralysis News and Research

Paralysis is the loss of muscle function in part of your body. It happens when something goes wrong with the way messages pass between your brain and muscles. Paralysis can be complete or partial. It can occur on one or both sides of your body. It can also occur in just one area, or it can be widespread. Paralysis of the lower half of your body, including both legs, is called paraplegia. Paralysis of the arms and legs is quadriplegia.
HKUST scientists find way to stimulate growth of corticospinal tract axons

HKUST scientists find way to stimulate growth of corticospinal tract axons

Researchers at the Hong Kong University of Science and Technology have found a way to stimulate the growth of axons, which may spell the dawn of a new beginning on chronic SCI treatments. [More]
ALS ACT initiative to speed discovery of new ALS treatments

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative. [More]
NGS technology helps identify new mitochondrial disease gene

NGS technology helps identify new mitochondrial disease gene

Next Generation Sequencing (NGS) technology offers an incredible opportunity for the rapid and relatively low-cost characterization of individual genomes, giving us a chance to make a substantial leap ahead in the molecular dissection of all mitochondrial disorders in humans. [More]
Researchers develop new implantable drug-delivery system using nanowire

Researchers develop new implantable drug-delivery system using nanowire

A team of researchers has created a new implantable drug-delivery system using nanowires that can be wirelessly controlled. [More]
Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford University researchers studying how the brain controls movement in people with paralysis, related to their diagnosis of Lou Gehrig's disease, have found that groups of neurons work together, firing in complex rhythms to signal muscles about when and where to move. [More]
Cosmetic surgery could improve lives of people with facial paralysis

Cosmetic surgery could improve lives of people with facial paralysis

A cosmetic surgery that uses injections of hyaluronic acid to make lips appear fuller could also improve the lives of people with facial paralysis, according to results of a small study by researchers at Johns Hopkins and Stanford universities. [More]
Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

A previously unknown link between the immune system and the death of motor neurons in Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been discovered by scientists at the CHUM Research Centre and the University of Montreal. The finding paves the way to a whole new approach for finding a drug that can cure or at least slow the progression of such neurodegenerative diseases as ALS, Alzheimer's, Parkinson's and Huntington's diseases. [More]
Stem cell transplant restores sensory functions in injured spinal cord

Stem cell transplant restores sensory functions in injured spinal cord

New research from Uppsala University shows promising progress in the use of stem cells for treatment of spinal cord injury. The results, which are published in the scientific journal Scientific Reports, show that human stem cells that are transplanted to the injured spinal cord contribute to restoration of some sensory functions. [More]
Researchers develop new technique to fabricate injectable electronic scaffolds

Researchers develop new technique to fabricate injectable electronic scaffolds

It's a notion that might be pulled from the pages of science-fiction novel - electronic devices that can be injected directly into the brain, or other body parts, and treat everything from neurodegenerative disorders to paralysis. [More]
University of Bonn researchers find way to stimulate larynx muscles using light

University of Bonn researchers find way to stimulate larynx muscles using light

Researchers at the University of Bonn have found a way to stimulate the larynx muscles of mice using light. In the long term, this method could be an option for the treatment of laryngeal paralysis, which causes difficulties in phonation and breathing. Their findings will be published in the scientific journal "Nature Communications." [More]
Modified poliovirus therapy for glioblastoma works best at a low dosage

Modified poliovirus therapy for glioblastoma works best at a low dosage

A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered. [More]
Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience. [More]
FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
3-D imaging technique may be useful for measuring efficacy of injectable wrinkle reducers

3-D imaging technique may be useful for measuring efficacy of injectable wrinkle reducers

A three-dimensional imaging technique often used in the automotive and aerospace industries for accurate measurement may be useful to measure the efficacy of injectable wrinkle reducers such as Botox and Dysport, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
RegenScientific gets FDA approval for Renu Gel injectable implant

RegenScientific gets FDA approval for Renu Gel injectable implant

RegenScientific announced that it has received FDA-clearance for its Renu Gel injectable implant indicated for vocal fold injection augmentation and today the company commenced shipments of this new product to physicians and hospitals in the United States. [More]
Just think about it: Giving natural movement to a patient with quadriplegia

Just think about it: Giving natural movement to a patient with quadriplegia

Paralysis is often the result of nerve damage that prevents commands from the brain being relayed to muscle to cause movement... [More]
Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. [More]
New research points to potential therapeutic target for treating multiple sclerosis

New research points to potential therapeutic target for treating multiple sclerosis

New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis. [More]
UAB opens third multidisciplinary clinic for transverse myelitis

UAB opens third multidisciplinary clinic for transverse myelitis

Mike Jezdimir knows firsthand how hard it is to get appropriate medical treatment for his condition, a disease of the spinal cord called transverse myelitis. He has had it for 48 years, since he was 17. TM is fairly uncommon, and many physicians rarely encounter it. Treatment options are limited. [More]
Advertisement
Advertisement